Astellas Wins FDA’s Fast-Track Tag for Primary Mitochondrial Myopathies Drug

Astellas Pharma said on October 20 that the US FDA has granted fast-track designation for ASP0367/MA-0211, which could potentially be the first-in-class treatment for primary mitochondrial myopathies (PMM). ASP0367 is an orally administered PPARδ modulator. It is expected to improve...read more